Histamine Toxicity Market Outlook:
Histamine Toxicity Market size was valued at USD 440.18 million in 2025 and is set to exceed USD 737.76 million by 2035, expanding at over 5.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of histamine toxicity is estimated at USD 461.18 million.
The growth in this market can be driven by an increase in consumption of seafood such as canned fish and the risk associated with its exposure to H.A.T. toxicity. According to estimates, 80% of fish consumed in the United States is imported from another country. It can also be said that the toxicity of histamine is intimately related to fish trade from all over the world.
The histamine toxicity market driven by a lack of internationally harmonized safety standards and awareness about the diseases associated with it. The development of the market for histamine toxicity is likely to be driven by a sufficient level of knowledge among food industry professionals regarding refrigeration and processing. In particular, people are not aware that expiry dates can be regarded as an important factor when buying food for cold storage. This is due to the lack of awareness, they occur more frequently in low-income countries.
Key Histamine Toxicity Market Insights Summary:
Regional Highlights:
- North America is anticipated to capture a 33% revenue share by 2035, driven by high seafood consumption and growing awareness of histamine intolerance.
- Europe is projected to hold a significant share by 2035, fueled by rising demand for frozen and canned fish and the development of novel diagnostics and treatments for histamine-related disorders.
Segment Insights:
- By 2035, the anti-histamine segment is projected to achieve the highest CAGR of 90%, driven by its widespread use in managing allergies, gastrointestinal disorders, and related symptoms.
- By 2035, the nasal segment is expected to secure a significant share, supported by its effectiveness in treating allergy-related symptoms with minimal side effects.
Key Growth Trends:
- Growing Prevalence of Food Allergies
- Lack of Safety Regulation on Fish Trade
Major Challenges:
- Uncertainties in Histamine Levels
- High Cost of Diagnostic Tests
Key Players: Travere Therapeutics, Inc., Alembic pharmaceuticals, Intas Pharmaceuticals Ltd, Sanofi Aventis Ltd, Cipla Limited, Actavis Inc.
Global Histamine Toxicity Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2025 Market Size: USD 440.18 million
- 2026 Market Size: USD 461.18 million
- Projected Market Size: USD 737.76 million by 2035
- Growth Forecasts: 5.3%
Key Regional Dynamics:
- Largest Region: North America (33% Share by 2035)
- Fastest Growing Region: Europe
- Dominating Countries: United States, China, Japan, Germany, United Kingdom
- Emerging Countries: India, South Korea, Brazil, Singapore, United Arab Emirates
Last updated on : 26 November, 2025
Histamine Toxicity Market - Growth Drivers and Challenges
Growth Drivers
- Growing Prevalence of Food Allergies - The increasing prevalence of food allergies increases the risk of histamine intolerance, a condition where individuals experience adverse reactions to dietary histamine. This creates a larger target audience for histamine detection kits and treatment options boosting the histamine toxicity market expansion in the forthcoming period. Researchers anticipate that 33 million Americans have food allergies, consisting of 5.6 million children under the age of 18.
- Lack of Safety Regulation on Fish Trade - Fish spoiling is caused by three main processes: oxidation, microbial growth, and enzymatic autolysis. The most widely used methods today for stopping oxidative, enzymatic, microbiological, and water activity deterioration are chemical methods and low-temperature preservation. Improper refrigeration during seafood shipment or seafood packaging may lead to histamine poisoning. As per a recent report, in 2022, the value of the world's seafood industry exceeded 257 billion US dollars. Therefore, for reasons related to the law, health, and environment, proper food labeling is crucial. Consumer interest in the precise ingredients of food that is sold has grown recently. Labels, along with other information that is frequently included, including energy values and nutritional information, are therefore crucial.
Challenges
- Uncertainties in Histamine Levels - The varying histamine content in different foods and its dependence on various storage and processing factors pose challenges for accurate quantification and risk assessment. This uncertainty impedes the development of standardized regulatory measures. This is predicted to hamper the growth of the histamine toxicity market in the future.
- High Cost of Diagnostic Tests are Predicted to Hamper the Market Growth in the Upcoming Period.
- Limited Treatment Options Availability are Set to Pose Limitations on the Market Expansion in the Forecast Period.
Histamine Toxicity Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
5.3% |
|
Base Year Market Size (2025) |
USD 440.18 million |
|
Forecast Year Market Size (2035) |
USD 737.76 million |
|
Regional Scope |
|
Histamine Toxicity Market Segmentation:
Drug Type Segment Analysis
In terms of drug type, the anti-histamine segment in the histamine toxicity market is predicted to hold the highest CAGR of 90% by the end of 2035. Histamine can cause symptoms such as sneezing, coughing, and watery eyes when an individual reacts badly to allergens such as pollen, fish, and animal dander. Anti-histamines are medications used to treat allergies as well as nausea, colds, anxiety, and other symptoms. Anti-histamines mainly fall into two categories. H-1 blockers or H-1 receptor antagonists are the first category. This category of antihistamines is used to reduce allergy symptoms. H-2 blockers or H-2 receptor antagonists are the second subtype. They are used to treat gastrointestinal disorders such as motion sickness, vomiting, nausea, gastritis, stomach ulcers, and gastroesophageal reflux disease. Hence, the growing use of anti-histamine for the treatment of different symptoms, is anticipated to boost the segment’s growth.
Route of Administration Segment Analysis
Histamine toxicity market from the nasal segment is predicted to hold a significant share during the estimated period. It rarely causes side effects, apart from a possible runny nose and bitter aftertaste. If an individual’s nose becomes irritated after using the spray, they can try a moisturizing nasal gel or switch to a different nasal gel. Most allergy symptoms such as sneezing, runny nose, itching, and stuffy nose can be treated with steroid sprays. One study found that over 75% of patients with histamine intolerance reported nasal symptoms. These are very popular treatments for histamine toxicity because they work very well and have very few negative side effects. These, along with taking antihistamines, are often the doctor's first suggestion. Considering the increasing benefits of nasal sprays, this segment is expected to reach new heights during the forecast period.
Our in-depth analysis of the global histamine toxicity market includes the following segments:
|
Drug Type |
|
|
Route of Administration |
|
|
Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Histamine Toxicity Market - Regional Analysis
North American Market Insights
North America industry is poised to account for largest revenue share of 33% by 2035, due to rising substantial consumption of seafood and canned fish in the region. North American have a growing appetite for seafood with fish consumption levels exceeding the global average. This increased consumption, particularly of canned fish and certain fish species with naturally high histamine levels directly impacts the market. According to the recently published National Fisheries Institute's Top 10 List of Seafood Consumption in 2021, Americans consumed a record twenty-five pounds of fish per capita, up 1.5 pounds from 2020. Furthermore, public awareness about histamine intolerance a condition where people struggle to metabolize histamine efficiently is on the rise. This awareness creates a demand for diagnostic tests and treatments comprising digestive diamine oxidase enzyme supplements that aid in histamine breakdown.
European Market Insights
The market in the Europe region is set to hold a significant share by the end of 2035. Due to the increased demand for frozen foods, much-canned fish is exported from Europe. The histamine toxicity market growth is to blame for all of these factors. In order to set quality standards, collaboration with the fishing community and public health authorities will be required. Besides, the European pharmaceutical and research institutions are actively engaged in developing novel treatments and diagnostics for histamine intolerance and related disorders contributing to market innovation. The availability of anti-histamines as OTC drugs in the region is also significantly driving the growth of the histamine toxicity market in the European region during the anticipated time period.
Histamine Toxicity Market Players:
- Johnson and Johnson company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Mylan Laboratories Ltd
- Neogen Corporation
- Pfizer Inc
- Travere Therapeutics, Inc.
- Alembic pharmaceuticals
- Intas Pharmaceuticals Ltd
- Sanofi Aventis Ltd
- Cipla Limited
- Actavis Inc.
Recent Developments
- Two new tests to detect Histamine have been launched by Neogen, Reveal for histamine and Reveal Q+ for histamine. Reveal and Reveal Q+ assays are easy to use lateral flow tests using a simple water extraction method, providing results in a matter of minutes and eliminating the need to dispose of any chemicals, as is required by other commercially available histamine detection methods, which reduce the time needed to test.
- Travere Therapeutics, Inc. reported that the US Food and Drug Administration granted accelerated approval for FILSPARRI to reduce proteinuria in adults with primary IgAN who are at risk of rapid disease progression, typically with a urine protein-to-creatinine ratio ≥1.5 g/g. This indication is given with accelerated approval based on reduction of proteinuria. It has not been established whether FILSPARI slows the decline in renal function in patients with IgAN. Continued approval of FILSPARI may require confirmation of clinical benefit in the ongoing Phase 3 PROTECT study, which is designed to show whether FILSPARI slows the decline in kidney function. Peak results from the two-year confirmatory endpoint of the PROTECT study are expected in the fourth quarter of 2023 and are intended to support traditional FILSPAR approval.
- Report ID: 5462
- Published Date: Nov 26, 2025
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
Histamine Toxicity Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.
Copyright @ 2025 Research Nester. All Rights Reserved.
Afghanistan (+93)
Åland Islands (+358)
Albania (+355)
Algeria (+213)
American Samoa (+1684)
Andorra (+376)
Angola (+244)
Anguilla (+1264)
Antarctica (+672)
Antigua and Barbuda (+1268)
Argentina (+54)
Armenia (+374)
Aruba (+297)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas (+1242)
Bahrain (+973)
Bangladesh (+880)
Barbados (+1246)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bermuda (+1441)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Bouvet Island (+)
Brazil (+55)
British Indian Ocean Territory (+246)
British Virgin Islands (+1284)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Cayman Islands (+1345)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China (+86)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Colombia (+57)
Comoros (+269)
Cook Islands (+682)
Costa Rica (+506)
Croatia (+385)
Cuba (+53)
Curaçao (+599)
Cyprus (+357)
Czechia (+420)
Democratic Republic of the Congo (+243)
Denmark (+45)
Djibouti (+253)
Dominica (+1767)
Dominican Republic (+1809)
Timor-Leste (+670)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Falkland Islands (+500)
Faroe Islands (+298)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Gibraltar (+350)
Greece (+30)
Greenland (+299)
Grenada (+1473)
Guadeloupe (+590)
Guam (+1671)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hong Kong (+852)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Isle of Man (+44)
Israel (+972)
Italy (+39)
Jamaica (+1876)
Japan (+81)
Jersey (+44)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macao (+853)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mayotte (+262)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Montserrat (+1664)
Morocco (+212)
Mozambique (+258)
Myanmar (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Caledonia (+687)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Niue (+683)
Norfolk Island (+672)
North Korea (+850)
Northern Mariana Islands (+1670)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Palestine (+970)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Puerto Rico (+1787)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Barthélemy (+590)
Saint Helena, Ascension and Tristan da Cunha (+290)
Saint Kitts and Nevis (+1869)
Saint Lucia (+1758)
Saint Martin (French part) (+590)
Saint Pierre and Miquelon (+508)
Saint Vincent and the Grenadines (+1784)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Sint Maarten (Dutch part) (+1721)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
South Georgia and the South Sandwich Islands (+0)
South Korea (+82)
South Sudan (+211)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Svalbard and Jan Mayen (+47)
Eswatini (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Taiwan (+886)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Togo (+228)
Tokelau (+690)
Tonga (+676)
Trinidad and Tobago (+1868)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Turks and Caicos Islands (+1649)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+39)
Venezuela (Bolivarian Republic of) (+58)
Vietnam (+84)
Wallis and Futuna (+681)
Western Sahara (+212)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)